Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)

References

• Sweet DE. Metabolic complications of antiretroviral therapy. Top HIV Med 2005;13:70–4.
   PubMedGoogle Scholar
• Strategies for Management of Anti-Retroviral Therapy/INSIGHT; DAD Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17–24.
   PubMed Web of Science ®Google Scholar
• Ciccarelli N, Fabbiani M, Di Giambenedetto S, Fanti I, Baldonero E, Bracciale L, et al. Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 2011;76:1403–9.
   PubMed Web of Science ®Google Scholar
• Winston J, Deray G, Hawkins T, Szczech L, Wyatt C, Young B. Kidney disease in patients with HIV infection and AIDS. Clin Infect Dis 2008;47:1449–57.
   PubMed Web of Science ®Google Scholar
• Gutiérrez F, Masiá M. The role of HIV and antiretroviral therapy in bone disease. AIDS Rev 2011;13:109–18.
   PubMed Web of Science ®Google Scholar
• Rockstroh JK, Lennox JL, Dejesus E, Saag MS, Lazzarin A, Wan H, et al. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis 2011; 53:807–16.
   PubMed Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Teppler H, Eron JJ, Gatell JM, Kumar PN, et al. Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010;50:605–12.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Di Giambenedetto S, Ragazzoni E, D’Ettorre G, Parruti G, Prosperi M, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. Pharmacol Res 2011;63:249–53.
   PubMed Web of Science ®Google Scholar
• Cattaneo D, Gervasoni C, Cozzi V, Baldelli S, Fucile S, Meraviglia P, et al. Co-administration of raltegravir reduces daily darunavir exposure in HIV-1 infected patients. Pharmacol Res 2012;65:198–203.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Navarra P, Cauda R, De Luca A, Di Giambenedetto S. Is there a drug–drug interaction between darunavir/ritonavir and raltegravir?. J Acquir Immune Defic Syndr 2012;60:e18–20.
   Web of Science ®Google Scholar
• Eron JJ, Young B, Cooper DA, Youle M, Dejesus E, Andrade-Villanueva J, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir–ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375: 396–407.
   PubMed Web of Science ®Google Scholar
• Martínez E, Larrousse M, Llibre JM, Gutiérrez F, Saumoy M, Antela A, et al. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study. AIDS 2010;24:1697–707.
   PubMed Web of Science ®Google Scholar
• Vispo E, Barreiro P, Maida I, Mena A, Blanco F, Rodríguez-Novoa S, et al. Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial. HIV Clin Trials 2010;11:197–204.
   PubMed Web of Science ®Google Scholar
• Gallien S, Braun J, Delaugerre C, Charreau I, Reynes J, Jeanblanc F, et al. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial. J Antimicrob Chemother 2011;66:2099–106.
   PubMed Web of Science ®Google Scholar
• Santos JR, Llibre JM, Ferrer E, Domingo P, Imaz A, Moltó J, et al. Efficacy and safety of switching from enfuvirtide to raltegravir in patients with virological suppression. HIV Clin Trials 2009;10:432–8.
   PubMed Web of Science ®Google Scholar
• Division of AIDS (DAIDS). Table for grading the severity of adult and pediatric adverse events. National Institutes of Health; December, 2004. Available at: www.niaid.nih.gov/LabsAndResources/resources/DAIDSClinRsrch/Documents/daidsaegradingtable.pdf (accessed 1 July 2013).
   Google Scholar
• Fortuna S, Ragazzoni E, Lisi L, Di Giambenedetto S, Fabbiani M, Navarra P. Validation of an UPLC-MS/MS method for quantitative analysis of raltegravir in human plasma samples. Ther Drug Monit 2013;35:258–63.
   PubMed Web of Science ®Google Scholar
• Fortuna S, Fabbiani M, Di Giambenedetto S, Ragazzoni E, Lisi L, Cauda R, et al. Variability of raltegravir plasma levels in the clinical setting. Pharmacology 2013;92:43–8.
   PubMed Web of Science ®Google Scholar
• Murri R, Cingolani A, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, et al. Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. J Acquir Immune Defic Syndr 2010;55:411–2.
   PubMed Web of Science ®Google Scholar
• Bartels C, Wegrzyn M, Wiedl A, Ackermann V, Ehrenreich H. Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing. BMC Neurosci 2010;11:118.
   PubMed Web of Science ®Google Scholar
• Grima P, Fabbiani M, Ciccarelli N, Tana M, Farina S, Colafigli M, et al. Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV- infected patients. J Infect 2012;65:439–46.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, et al. Cardiovascular risk factors and carotid intima-media thickness are associated to lower cognitive performance in HIV-infected patients. HIV Med 2013;14: 136–44.
   PubMed Web of Science ®Google Scholar
• Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS 2010;24:223–30.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Fabbiani M, Colafigli M, Ciccarelli N, Farina S, Sidella L, et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother 2013;68:1364–72.
   PubMed Web of Science ®Google Scholar
• Calza L, Manfredi R, Colangeli V, Pocaterra D, Rosseti N, Pavoni M, et al. Efficacy and safety of atazanavir–ritonavir plus abacavir–lamivudine or tenofovir–emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue. AIDS Patient Care STDS 2009;23:691–7.
   PubMed Web of Science ®Google Scholar
• Martínez E, Arranz JA, Podzamczer D, Loncá M, Sanz J, Barragán P, et al. A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression. J Acquir Immune Defic Syndr 2009;51:290–7.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, Daar ES, Mollan K, Budhathoki C, et al. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results. J Infect Dis 2011;204: 1191–201.
   PubMed Web of Science ®Google Scholar
• Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009;23:1547–56.
   PubMed Web of Science ®Google Scholar
• Post FA, Moyle GJ, Stellbrink HJ, Domingo P, Podzamczer D, Fisher M, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010;55:49–57.
   PubMed Web of Science ®Google Scholar
• Pérez-Molina JA, Serrano O, Milinkovic A, Domingo P, Currán A, Knobel H, et al. Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) pairs in HIV-infected patients initiating rescue therapy (The NUCREST Study). HIV Clin Trials 2010;11:294–302.
   PubMed Web of Science ®Google Scholar
• Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir–lamivudine versus tenofovir–emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361:2230–40.
   PubMed Web of Science ®Google Scholar
• Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, Tonelli M. Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51:496–505.
   PubMed Web of Science ®Google Scholar
• Tungsiripat M, Kitch D, Glesby MJ, Gupta SK, Mellors JW, Moran L, et al. A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206. AIDS 2010;24:1781–4.
   PubMed Web of Science ®Google Scholar
• Fabbiani M, Bracciale L, Doino M, Sidella L, Farina S, Di Cristo V, et al. Lipid-lowering effect of tenofovir in HIV-infected patients. J Antimicrob Chemother 2011;66: 682–3.
   PubMed Web of Science ®Google Scholar
• Dahl V, Lee E, Peterson J, Spudich SS, Leppla I, Sinclair E, et al. Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis 2011;204: 1936–45.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A, Aweeka F, et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009;4:e6877.
   PubMed Web of Science ®Google Scholar
• Lennox JL, Dejesus E, Berger DS , Lazzarin A, Pollard RB, Ramalho Madruga JV, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55:39–48.
   PubMed Web of Science ®Google Scholar
• Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS 2012;26:475–81.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, Komarow L, Powderly WG, Klingman K, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 2009;23:1109–18.
   PubMed Web of Science ®Google Scholar
• Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841–50.
   PubMed Web of Science ®Google Scholar